Summit Therapeutics Plc (SUMM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Date: October 12, 2018
Pages: 81
Price:
US$ 250.00
License [?]:
Publisher: GlobalData
Report type: Company Report
Delivery: E-mail Delivery (PDF)
ID: SAC107475BEEN
Leaflet:

Download PDF Leaflet

Summit Therapeutics Plc (SUMM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Summary

Summit Therapeutics Plc (Summit), formerly Summit Corp Plc is a clinical-stage drug discovery and development company that offer therapies. The company conducts research and development on the treatment of rare diseases and infectious diseases including duchenne muscular dystrophy and the infectious disease caused by the bacteria C difficile. It develops ridinilazole, an antibiotic that has the potential to treat CDI and reduce disease recurrence. Summit undertakes utrophin modulation program for duchenne muscular dystrophy. The company also develops novel antibiotic program for the treatment of superbug C. difficile. It operates through other pharmaceutical companies and charity foundations and parent advocacy groups. The company operates through its office located in Cambridge, the US. Summit is headquartered in Abingdon, the UK.

Summit Therapeutics Plc (SUMM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope
  • Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
  • Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
  • Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
  • Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
  • Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
  • Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
  • Business Description - A brief description of the company's operations.
  • Key Employees - A list of the key executives of the company.
  • Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
  • Key Competitors - A list of the key competitors of the company.
  • Key Recent Developments - A brief on recent news about the company.
Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
  • The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion/divestiture strategy
  • The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
  • Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
  • The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
  • Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
  • Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company.

NOTE: Out of security concerns GlobalData requires using corporate email address.
Summit Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Summit Therapeutics Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018
Summit Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018
Summit Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018
Summit Therapeutics Plc, Medical Devices Deals, 2012 to YTD 2018
Summit Therapeutics Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018
Summit Therapeutics Plc, Pharmaceuticals & Healthcare, Deal Details
Partnerships
Summit (Oxford) Enters into Contract with Biomedical Advanced Research and Development Authority
Summit Therapeutics Enters into Agreement with University of Oxford
Licensing Agreements
Summit Therapeutics Enters into Licensing Agreement with Eurofarma Laboratorios
Sarepta Therapeutics Enters into Licensing Agreement with Summit Therapeutics
Roche Expands its Licensing Agreement with Discuva
Summit Enters Into Licensing Agreement With Bristol-Myers Squibb For Seglin Technology
Equity Offering
Summit Therapeutics Plans to Raise up to USD225 Million in Public offering of Securities
Summit Therapeutics Raises USD21.3 Million in Private Placement of Shares
Summit Therapeutics Raises USD20.1 Million in Public Offering of Shares
Summit Therapeutics Raises Funds in Private Placement of Shares upon Exercise of Warrants
Summit Therapeutics Raises USD0.1 Million in Private Placement of Shares upon Exercise of Warrants
Summit Therapeutics Completes Initial Public Offering of American Depositary Shares
Summit Therapeutics Raises USD36.6 Million in Private Placement of Shares
Summit Completes Private Placement Of Shares For US$34.4 Million
Summit Completes Private Placement Of Shares For US$1.6 Million
Summit Completes Private Placement Of Shares For US$7 Million
Summit Completes Private Placement Of Shares For US$0.1 Million
Summit Announces Private Placement Of Shares For US$8 Million
Acquisition
Summit Therapeutics Acquires Discuva for USD13.3 Million
Summit Acquires MuOx for USD5.3 Million
Summit Therapeutics Plc - Key Competitors
Summit Therapeutics Plc - Key Employees
Summit Therapeutics Plc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Financial Announcements
Sep 20, 2018: Summit Therapeutics reports financial results for the second quarter ended 31 July 2018 and operational progress
Jun 05, 2018: Summit Therapeutics Reports Financial Results for the First Quarter Ended 30 April 2018 and Operational Progress
Apr 11, 2018: Summit Therapeutics Reports Financial Results for the Fiscal Year Ended 31 January 2018
Apr 11, 2018: Summit Therapeutics Reports Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2018 and Operational Progress
Dec 06, 2017: Summit Therapeutics Reports Financial Results for the Third Quarter and Nine Months Ended 31 October 2017 and Operational Progress
Aug 31, 2017: Summit Therapeutics Reports Financial Results For The Second Quarter And Half Year Ended 31 July 2017 And Operational Progress
Jun 14, 2017: Summit Therapeutics Reports Financial Results For The First Quarter Ended 30 April 2017 And Operational Progress
Mar 29, 2017: Summit Therapeutics Reports 4th Quarter and Year End Financial Results and Operational Progress
Corporate Communications
May 23, 2017: Summit Announces Key Appointments to Strengthen Research & Development Team
Jan 18, 2017: Summit Appoints Dr David Roblin as Chief Operating Officer and President of Research & Development
Government and Public Interest
Jul 10, 2018: Summit Therapeutics Wins up to $4.5 Million Grant from CARB-X for Development of New Mechanism Gonorrhoea Antibiotics
Product News
09/05/2018: Summit nominates new mechanism antibiotic SMT-571 as its lead clinical candidate for the treatment of gonorrhoea
04/23/2018: Summit Highlights Discovery of a Series of New Mechanism Antibiotics for the Treatment of Gonorrhoea in Late-Breaking Presentation at ECCMID 2018
Mar 13, 2018: Summit’s Infectious Diseases Technology Platform Yields Novel Antibiotics with Potential in Global Fight Against Gonorrhoea
Clinical Trials
Nov 20, 2017: Summit Completes Initial 24 Weeks Of Dosing Of Ezutromid In Patients With DMD In Phaseout DMD Clinical Trial
Oct 04, 2017: Summit Highlights DMD Biomarker Validation Data and Phase 2 Clinical Trial Baseline Characteristics in Presentations at 22nd WMS Congress
Sep 25, 2017: Summit Joins cTAP In Collaborative Effort To Enhance The Development Of Utrophin Modulators And Other Treatments For Duchenne Muscular Dystrophy
Jun 22, 2017: Summit Presents Data From Phase 1 Clinical Programme of Ezutromid at the European Paediatric Neurology Society Congress
May 15, 2017: Summit Completes Enrolment of PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid in Patients with DMD
Mar 27, 2017: Summit to Extend Ongoing PhaseOut DMD Clinical Trial of Ezutromid in Patients with DMD
Other Significant Developments
Sep 06, 2018: Summit Discovers multiple new mechanism antibiotics against novel ESKAPE pathogen targets
Mar 30, 2017: Summit Therapeutics: Change of Registered Office
Mar 30, 2017: Summit Announces Change Of Registered Company Address
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Summit Therapeutics Plc, Pharmaceuticals & Healthcare, Key Facts, 2018
Summit Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Summit Therapeutics Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018
Summit Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018
Summit Therapeutics Plc, Deals By Therapy Area, 2012 to YTD 2018
Summit Therapeutics Plc, Medical Devices Deals, 2012 to YTD 2018
Summit Therapeutics Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018
Summit (Oxford) Enters into Contract with Biomedical Advanced Research and Development Authority
Summit Therapeutics Enters into Agreement with University of Oxford
Summit Therapeutics Enters into Licensing Agreement with Eurofarma Laboratorios
Sarepta Therapeutics Enters into Licensing Agreement with Summit Therapeutics
Roche Expands its Licensing Agreement with Discuva
Summit Enters Into Licensing Agreement With Bristol-Myers Squibb For Seglin Technology
Summit Therapeutics Plans to Raise up to USD225 Million in Public offering of Securities
Summit Therapeutics Raises USD21.3 Million in Private Placement of Shares
Summit Therapeutics Raises USD20.1 Million in Public Offering of Shares
Summit Therapeutics Raises Funds in Private Placement of Shares upon Exercise of Warrants
Summit Therapeutics Raises USD0.1 Million in Private Placement of Shares upon Exercise of Warrants
Summit Therapeutics Completes Initial Public Offering of American Depositary Shares
Summit Therapeutics Raises USD36.6 Million in Private Placement of Shares
Summit Completes Private Placement Of Shares For US$34.4 Million
Summit Completes Private Placement Of Shares For US$1.6 Million
Summit Completes Private Placement Of Shares For US$7 Million
Summit Completes Private Placement Of Shares For US$0.1 Million
Summit Announces Private Placement Of Shares For US$8 Million
Summit Therapeutics Acquires Discuva for USD13.3 Million
Summit Acquires MuOx for USD5.3 Million
Summit Therapeutics Plc, Key Competitors
Summit Therapeutics Plc, Key Employees
Summit Therapeutics Plc, Other Locations
Summit Therapeutics Plc, Subsidiaries

LIST OF FIGURES

Summit Therapeutics Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018
Summit Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Summit Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018
Summit Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018
Summit Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Summit Therapeutics Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018
Summit Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018
Summit Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018
Summit Therapeutics Plc, Medical Devices Deals, 2012 to YTD 2018
Skip to top


Ask Your Question

Summit Therapeutics Plc (SUMM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: